Eli Lilly and Company vs Vericel Corporation: A Gross Profit Performance Breakdown

Eli Lilly vs Vericel: A Decade of Gross Profit Growth

__timestampEli Lilly and CompanyVericel Corporation
Wednesday, January 1, 20141468310000011503000
Thursday, January 1, 20151492150000024698000
Friday, January 1, 20161556720000026076000
Sunday, January 1, 20171680110000033570000
Monday, January 1, 20181681160000058697000
Tuesday, January 1, 20191759830000080279000
Wednesday, January 1, 20201905650000084228000
Friday, January 1, 202121005600000106025000
Saturday, January 1, 202221911600000109788000
Sunday, January 1, 202327041900000135576000
Monday, January 1, 202436624400001
Loading chart...

Igniting the spark of knowledge

A Tale of Two Companies: Eli Lilly and Vericel's Gross Profit Journey

In the competitive landscape of the pharmaceutical industry, Eli Lilly and Company and Vericel Corporation present a fascinating study in contrasts. Over the past decade, Eli Lilly has demonstrated a robust growth trajectory, with its gross profit surging by approximately 84% from 2014 to 2023. This growth underscores its strategic prowess and market dominance. In stark contrast, Vericel Corporation, while significantly smaller, has shown a remarkable upward trend, increasing its gross profit by over 1,000% during the same period. This impressive growth, albeit from a smaller base, highlights Vericel's potential and agility in the market. As of 2023, Eli Lilly's gross profit stands at a towering 27 billion, while Vericel's reaches a commendable 136 million. This comparison not only showcases the scale of Eli Lilly but also the promising trajectory of Vericel in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025